RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recently received attention in an article on Psychiatrist.com, which discussed the potential of its pipeline products, NRX-100 and NRX-101, in addressing bipolar depression and suicidal ideation. The article, entitled “How NRx Could Upend the Fight Against Depression and Suicide,” hosted by the Journal of Clinical Psychiatry, emphasized the clinical relevance of these promising treatments.
NRX-101, described as a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone, has shown higher efficacy than lurasidone alone in reducing akathisia and suicidality among patients with treatment-resistant bipolar depression.
Meanwhile, NRX-100, a proprietary preservative-free IV formulation of ketamine, is under investigation as a potential treatment for acute suicidal crises in depression. These developments represent significant strides in mental health treatment and offer hope for those affected by these challenging conditions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.